• Bleeding disorders

Koate-dvi Generic Name & Formulations

General Description

Antihemophilic Factor VIII (human) 250 IU, 500 IU, 1000 IU; per bottle; dried concentrate for IV infusion after reconstitution; contains albumin.

Pharmacological Class

Clotting factor.

How Supplied

Single-dose bottle—1 (w. diluent)

Koate-dvi Indications


Prevention and control of hemorrhagic episodes or in order to perform emergency or elective surgery in Hemophilia A patients.

Koate-dvi Dosage and Administration


Dosage Required (IU) = Body Weight (kg) × Desired % Factor VIII Increase × 0.5. Individualize. Infuse over 5–10 minutes if tolerated. Use filter needle. Hemorrhage: Mild: 10 IU/kg as single dose. Moderate: 15–25 IU/kg, then 10–15 IU/kg every 8–12hrs if needed. Severe: initially 40–50 IU/kg, then 20–25 IU/kg every 8–12hrs. Major surgery: pre-op dose: 50 IU/kg, then verify Factor VIII level achieved prior to surgery; may repeat every 6–12hrs initially and for 10–14 days until healing complete.


Not recommended.

Koate-dvi Contraindications

Not Applicable

Koate-dvi Boxed Warnings

Not Applicable

Koate-dvi Warnings/Precautions


Not for von Willebrand's disease. Confirm Factor VIII deficiency prior to treatment. Contains human plasma; monitor for possible infection transmission. Large or frequent doses: monitor hematocrit for signs of progressive anemia. Monitor for development of Factor VIII inhibitors. Pregnancy (Cat.C).

Koate-dvi Pharmacokinetics

See Literature

Koate-dvi Interactions

Koate-dvi Adverse Reactions

Adverse Reactions

Allergic reactions, tingling sensations, blurred vision, headache, GI upset, jittery feeling, antibody formation.

Koate-dvi Clinical Trials

See Literature

Koate-dvi Note

Not Applicable

Koate-dvi Patient Counseling

See Literature